Luminex Corporation recently announced preliminary results for fourth-quarter 2018, wherein the top line surpassed the Zacks Consensus Estimate.
Revenues are anticipated to total $81 million, way above the Zacks Consensus Estimate of $77.9 million.
The company is scheduled to release full financial results on Feb 4.
Happy Investors
Luminex’s fourth-quarter preliminary results seem to impress investors. The Zacks Rank #3 (Hold) stock rose 2.2% to $24.24 at close after the release of the results. If the company manages to outpace the Zacks Consensus Estimate in the fourth quarter, it will mark the first beat since the last reported quarter.
Over the past year, the stock has rallied 16.8% compared with the industry’s 0.4% rise. The current level also compares favorably with the S&P 500 index’s 7.1% decline.
Highlights
Total Licensed Technologies Group revenues grew 23% year over year to more than $41 million. Total MDx revenues of approximately $39 million declined 11% year over year. Excluding the departure of LabCorp, total MDx revenues increased by approximately 21% year over year.
Full-Year Results
On a full-year basis, Luminex expects revenues to exceed $315 million, near the high end of the previous guidance of $310-$316 million. Notably, the figure comes above the Zacks Consensus Estimate of $312.6 million.
Per management, total Licensed Technologies Group revenues of $149 million grew 5% year over year. Total MDx revenues of approximately $164 million inched up 1% year over year. Excluding the departure of LabCorp, total MDx revenues were up approximately 13% on a year-over-year basis.
Guidance
For 2019, Luminex expects revenues within $337-$343 million. The Zacks Consensus Estimate is pegged at $332.5 million, below the guided range.
Notably, the guidance includes contributions from the flow cytometry business purchased from MilliporeSigma.
Key Picks
A few better-ranked stocks in the broader medical space are Veeva Systems Inc (VEEV - Free Report) , Penumbra, Inc. (PEN - Free Report) and OPKO Health, Inc (OPK - Free Report) . While, Veeva Systems and OPKO Health sport a Zacks Rank #1 (Strong Buy), Penumbra carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Veeva Systems’ long-term earnings growth rate is projected at 19.5%.
Penumbra has a long-term earnings growth rate of 20%.
OPKO Health’s long-term earnings growth rate is projected at 12%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Luminex Corporation recently announced preliminary results for fourth-quarter 2018, wherein the top line surpassed the Zacks Consensus Estimate.
Revenues are anticipated to total $81 million, way above the Zacks Consensus Estimate of $77.9 million.
The company is scheduled to release full financial results on Feb 4.
Happy Investors
Luminex’s fourth-quarter preliminary results seem to impress investors. The Zacks Rank #3 (Hold) stock rose 2.2% to $24.24 at close after the release of the results. If the company manages to outpace the Zacks Consensus Estimate in the fourth quarter, it will mark the first beat since the last reported quarter.
Over the past year, the stock has rallied 16.8% compared with the industry’s 0.4% rise. The current level also compares favorably with the S&P 500 index’s 7.1% decline.
Highlights
Total Licensed Technologies Group revenues grew 23% year over year to more than $41 million. Total MDx revenues of approximately $39 million declined 11% year over year. Excluding the departure of LabCorp, total MDx revenues increased by approximately 21% year over year.
Full-Year Results
On a full-year basis, Luminex expects revenues to exceed $315 million, near the high end of the previous guidance of $310-$316 million. Notably, the figure comes above the Zacks Consensus Estimate of $312.6 million.
Per management, total Licensed Technologies Group revenues of $149 million grew 5% year over year. Total MDx revenues of approximately $164 million inched up 1% year over year. Excluding the departure of LabCorp, total MDx revenues were up approximately 13% on a year-over-year basis.
Guidance
For 2019, Luminex expects revenues within $337-$343 million. The Zacks Consensus Estimate is pegged at $332.5 million, below the guided range.
Notably, the guidance includes contributions from the flow cytometry business purchased from MilliporeSigma.
Key Picks
A few better-ranked stocks in the broader medical space are Veeva Systems Inc (VEEV - Free Report) , Penumbra, Inc. (PEN - Free Report) and OPKO Health, Inc (OPK - Free Report) . While, Veeva Systems and OPKO Health sport a Zacks Rank #1 (Strong Buy), Penumbra carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Veeva Systems’ long-term earnings growth rate is projected at 19.5%.
Penumbra has a long-term earnings growth rate of 20%.
OPKO Health’s long-term earnings growth rate is projected at 12%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on OPK - FREE
Get the latest research report on VEEV - FREE
Get the latest research report on PEN - FREE